Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Neck lymph vessel surgery for people with moderate Alzheimer's disease

Tests a neck lymph-to-vein surgery plus usual care in moderate Alzheimer's disease.

Key facts

Who runs it
Southwest Hospital, China
Where
Chongqing, ChinaSee the site
Trial code
Registry title
Deep Cervical Lymphovenous Anastomosis for Moderate Alzheimer's Disease
Status
Not yet recruiting
People taking part
296 people, planned
Started
1 Jul 2026
Expected to end
30 Jun 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Deep cervical lymphovenous anastomosis (LVA)
  • Routine Treatment
Record updated
22 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 to 80 with moderate Alzheimer's disease who are already on stable standard treatment. It tests a neck lymph-vessel surgery added to routine care.

Age
50 to 80 years
Sex
Men and women
Disease stage
Moderate probable Alzheimer's disease (NIA-AA criteria), MMSE score between 10 and 20, memory and thinking decline for at least 6 months.
Earlier treatment
Must have had stable routine anti-dementia drug treatment for more than 6 months without obvious clinical improvement.

Main reasons for not taking part

  • Severe heart, liver, kidney, lung or blood-forming organ problems that make surgery or anesthesia unsafe
  • Past brain surgery, severe head injury, stroke, brain tumor or other brain and nerve diseases
  • Other types of dementia, such as vascular, frontotemporal, Lewy body or mixed dementia
  • Pregnancy or breastfeeding
  • Taking part in another interventional trial within 3 months before enrollment

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Aged 50 to 80 years old, male or female
  • Clinically diagnosed with moderate probable Alzheimer's disease according to the NIA-AA criteria
  • Baseline Mini-Mental State Examination (MMSE) score between 10 and 20 points
  • Clinical cognitive decline duration of at least 6 months
  • Stable routine anti-dementia drug treatment for more than 6 months without obvious clinical improvement
  • Able to complete neuropsychological scale assessments, blood biomarker detection and Aβ-PET examination
  • Have a reliable caregiver who can accompany follow-up visits and assist in completing evaluations
  • The participant or legal surrogate voluntarily signs the written informed consent

Who cannot take part

  • Participation in other interventional clinical trials within 3 months before enrollment
  • Severe cardiac, hepatic, renal, respiratory or hematopoietic system dysfunction unable to tolerate surgery or anesthesia
  • A history of intracranial surgery, severe craniocerebral trauma, stroke, brain tumor or other central nervous system diseases
  • Other types of dementia, including vascular dementia, frontotemporal dementia, Lewy body dementia, or mixed dementia
  • Psychiatric disorders requiring long-term medication that may affect cognitive assessment results
  • Contraindications for PET imaging or contrast agent allergy
  • Active infection, malignant tumor or severe wasting disease
  • Any other condition judged inappropriate for enrollment by the investigator
  • Pregnancy or breastfeeding status
  • Poor compliance or inability to complete scheduled follow-up

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 80 years old?

Where in China

  • The First Affiliated Hospital of Army Medical University (Southwest Hospital)Chongqing, ChinaContact: Jingyu Chen, DrNo longer taking part

About the trial

What the trial wants to find out

This is a multicenter, prospective, open-label, endpoint-blinded randomized controlled clinical study. We aim to evaluate the safety and efficacy of deep cervical lymphovenous anastomosis (LVA) combined with routine treatment for patients with moderate Alzheimer's disease, compared with routine treatment alone.

Read full original descriptionShow less

A total of 296 eligible participants aged 50 to 80 years with moderate Alzheimer's disease will be enrolled and randomly divided into two groups at a 1:1 ratio. One group will receive deep cervical lymphovenous anastomosis plus standard routine treatment, while the other group will only receive standard routine treatment for Alzheimer's disease.

All participants will be followed up for 12 months after randomization. We will assess cognitive function using MMSE and CDR-SB scales, evaluate caregiver burden via ZBI scale, and detect changes in Alzheimer's disease related biomarkers including blood amyloid-beta and tau protein, as well as Aβ-PET imaging indicators. The main goal is to observe whether this surgical procedure can improve patients' neurological function and clear abnormal protein deposits in the brain, and confirm its long-term safety.

This study strictly follows ethical principles. Every participant or their legal representative will sign a written informed consent before enrollment. During the whole study period, we will closely monitor all adverse events to ensure the safety of participants.

The 2 groups in the trial

  • Intervention Group (Surgery plus routine treatment)Treatment being tested

    Participants undergo bilateral deep cervical lymphovenous anastomosis (LVA), combined with standard routine drug treatment for moderate Alzheimer's disease.

    Treatment: Deep cervical lymphovenous anastomosis (LVA) and Routine Treatment

  • Control Group (Routine treatment only)Existing treatment, for comparison

    Participants receive only standard routine drug treatment for moderate Alzheimer's disease, with no surgical procedure performed.

    Treatment: Routine Treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Efficacy and Safety of Deep Cervical LYMphatic-Venous Anastomosis for Moderate Alzheimer's Disease: A Multicenter, Prospective, Randomized Controlled Trial
Plain-language title
Neck lymph vessel surgery for people with moderate Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07658430, who can take part
Record updated
22 June 2026